drugset
drugset / Trial / NCT05117489

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05117489 ↗

Phase 1 Completed 70 enrolled Corcept Therapeutics
Non-randomizedSequentialOpen-labelTreatment

Summary

This phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)

Timeline

Start
2021-11-23
Primary completion
2024-01-29
Completion
2024-01-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Miricorilant Small molecule 10 mg Oral
Subject Miricorilant Small molecule 50 mg Oral
Subject Miricorilant Small molecule 100 mg Oral
Subject Miricorilant Small molecule 150 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis